HomeEYPT • NASDAQ
Eyepoint Pharmaceuticals Inc
$8.95
After Hours:
$9.08
(1.45%)+0.13
Closed: Nov 22, 6:19:48 PM GMT-5 · USD · NASDAQ · Disclaimer
StockUS listed securityUS headquartered
Previous close
$8.35
Day range
$8.20 - $9.32
Year range
$5.87 - $30.99
Market cap
609.46M USD
Avg Volume
1.10M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
(USD)Sep 2024Y/Y change
Revenue
10.52M-30.77%
Operating expense
13.96M23.25%
Net income
-29.36M-132.80%
Net profit margin
-278.99-236.29%
Earnings per share
-0.54-63.64%
EBITDA
-32.34M-126.42%
Effective tax rate
Total assets
Total liabilities
(USD)Sep 2024Y/Y change
Cash and short-term investments
253.79M86.60%
Total assets
300.92M88.02%
Total liabilities
82.18M-18.97%
Total equity
218.73M
Shares outstanding
68.25M
Price to book
2.04
Return on assets
-26.19%
Return on capital
-33.18%
Net change in cash
(USD)Sep 2024Y/Y change
Net income
-29.36M-132.80%
Cash from operations
-39.03M-156.70%
Cash from investing
16.20M1,041.63%
Cash from financing
11.89M14.78%
Net change in cash
-10.94M-66.70%
Free cash flow
-27.63M-1,572.56%
About
EyePoint Pharmaceuticals, Inc. pSivida is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems and nanotechnology to drug delivery. pSivida obtained porous silicon technology from the British government Defence Evaluation and Research Agency. QinetiQ continues to be a strategic partner. In June 2004, pSivida acquired full ownership of pSiMedica. In April 2018, pSivida purchased eye products firm Icon Bioscience. Wikipedia
Founded
1987
Employees
121
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu